Trial Profile
A Phase II Open-Labeled Study to Evaluate BFPET as a Myocardial Perfusion Imaging Agent for the Evaluation of Coronary Artery Disease
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2020
Price :
$35
*
At a glance
- Drugs BFPET (Primary)
- Indications Coronary artery disease
- Focus Diagnostic use
- Sponsors FluoroPharma
- 31 Jul 2018 Planned End Date changed from 30 Jun 2019 to 30 Sep 2019.
- 31 Jul 2018 Planned primary completion date changed from 30 Dec 2018 to 30 May 2019.
- 31 Jul 2018 Planned initiation date changed from 30 Jun 2018 to 1 Oct 2018.